Clinical outcomes of a novel therapeutic vaccine with Tax peptide-pulsed dendritic cells for adult T cell leukaemia/lymphoma in a pilot study

Youko Suehiro, Atsuhiko Hasegawa, Tadafumi Iino, Amane Sasada, Nobukazu Watanabe, Masao Matsuoka, Ayako Takamori, Ryuji Tanosaki, Atae Utsunomiya, Ilseung Choi, Tetsuya Fukuda, Osamu Miura, Shigeo Takaishi, Takanori Teshima, Koichi Akashi, Mari Kannagi, Naokuni Uike, Jun Okamura

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Adult T cell leukaemia/lymphoma (ATL) is a human T cell leukaemia virus type-I (HTLV-I)-infected T cell malignancy with poor prognosis. We herein developed a novel therapeutic vaccine designed to augment an HTLV-I Tax-specific cytotoxic T lymphocyte (CTL) response that has been implicated in anti-ATL effects, and conducted a pilot study to investigate its safety and efficacy. Three previously treated ATL patients, classified as intermediate- to high-risk, were subcutaneously administered with the vaccine, consisting of autologous dendritic cells (DCs) pulsed with Tax peptides corresponding to the CTL epitopes. In all patients, the performance status improved after vaccination without severe adverse events, and Tax-specific CTL responses were observed with peaks at 16-20 weeks. Two patients achieved partial remission in the first 8 weeks, one of whom later achieved complete remission, maintaining their remission status without any additional chemotherapy 24 and 19 months after vaccination, respectively. The third patient, whose tumour cells lacked the ability to express Tax at biopsy, obtained stable disease in the first 8 weeks and later developed slowly progressive disease although additional therapy was not required for 14 months. The clinical outcomes of this pilot study indicate that the Tax peptide-pulsed DC vaccine is a safe and promising immunotherapy for ATL.

Original languageEnglish
Pages (from-to)356-367
Number of pages12
JournalBritish Journal of Haematology
Volume169
Issue number3
DOIs
Publication statusPublished - 2015 May 1
Externally publishedYes

Fingerprint

Adult T Cell Leukemia Lymphoma
Dendritic Cells
Cytotoxic T-Lymphocytes
Vaccines
Human T-lymphotropic virus 1
Vaccination
T-Lymphocyte Epitopes
Therapeutics
Immunotherapy
Neoplasms
Outcome Assessment (Health Care)
T-Lymphocytes
Biopsy
Safety
Drug Therapy
leucyl-leucyl-phenylalanyl-glycyl-tyrosyl-prolyl-valyl-tyrosyl-valine

Keywords

  • Adult T cell leukaemia/lymphoma
  • Cytotoxic T lymphocyte
  • Dendritic cell
  • Human T cell leukaemia virus type-I
  • Tumour vaccine

ASJC Scopus subject areas

  • Hematology

Cite this

Clinical outcomes of a novel therapeutic vaccine with Tax peptide-pulsed dendritic cells for adult T cell leukaemia/lymphoma in a pilot study. / Suehiro, Youko; Hasegawa, Atsuhiko; Iino, Tadafumi; Sasada, Amane; Watanabe, Nobukazu; Matsuoka, Masao; Takamori, Ayako; Tanosaki, Ryuji; Utsunomiya, Atae; Choi, Ilseung; Fukuda, Tetsuya; Miura, Osamu; Takaishi, Shigeo; Teshima, Takanori; Akashi, Koichi; Kannagi, Mari; Uike, Naokuni; Okamura, Jun.

In: British Journal of Haematology, Vol. 169, No. 3, 01.05.2015, p. 356-367.

Research output: Contribution to journalArticle

Suehiro, Y, Hasegawa, A, Iino, T, Sasada, A, Watanabe, N, Matsuoka, M, Takamori, A, Tanosaki, R, Utsunomiya, A, Choi, I, Fukuda, T, Miura, O, Takaishi, S, Teshima, T, Akashi, K, Kannagi, M, Uike, N & Okamura, J 2015, 'Clinical outcomes of a novel therapeutic vaccine with Tax peptide-pulsed dendritic cells for adult T cell leukaemia/lymphoma in a pilot study', British Journal of Haematology, vol. 169, no. 3, pp. 356-367. https://doi.org/10.1111/bjh.13302
Suehiro, Youko ; Hasegawa, Atsuhiko ; Iino, Tadafumi ; Sasada, Amane ; Watanabe, Nobukazu ; Matsuoka, Masao ; Takamori, Ayako ; Tanosaki, Ryuji ; Utsunomiya, Atae ; Choi, Ilseung ; Fukuda, Tetsuya ; Miura, Osamu ; Takaishi, Shigeo ; Teshima, Takanori ; Akashi, Koichi ; Kannagi, Mari ; Uike, Naokuni ; Okamura, Jun. / Clinical outcomes of a novel therapeutic vaccine with Tax peptide-pulsed dendritic cells for adult T cell leukaemia/lymphoma in a pilot study. In: British Journal of Haematology. 2015 ; Vol. 169, No. 3. pp. 356-367.
@article{40278005b85f4366a4f88cdd22b85940,
title = "Clinical outcomes of a novel therapeutic vaccine with Tax peptide-pulsed dendritic cells for adult T cell leukaemia/lymphoma in a pilot study",
abstract = "Adult T cell leukaemia/lymphoma (ATL) is a human T cell leukaemia virus type-I (HTLV-I)-infected T cell malignancy with poor prognosis. We herein developed a novel therapeutic vaccine designed to augment an HTLV-I Tax-specific cytotoxic T lymphocyte (CTL) response that has been implicated in anti-ATL effects, and conducted a pilot study to investigate its safety and efficacy. Three previously treated ATL patients, classified as intermediate- to high-risk, were subcutaneously administered with the vaccine, consisting of autologous dendritic cells (DCs) pulsed with Tax peptides corresponding to the CTL epitopes. In all patients, the performance status improved after vaccination without severe adverse events, and Tax-specific CTL responses were observed with peaks at 16-20 weeks. Two patients achieved partial remission in the first 8 weeks, one of whom later achieved complete remission, maintaining their remission status without any additional chemotherapy 24 and 19 months after vaccination, respectively. The third patient, whose tumour cells lacked the ability to express Tax at biopsy, obtained stable disease in the first 8 weeks and later developed slowly progressive disease although additional therapy was not required for 14 months. The clinical outcomes of this pilot study indicate that the Tax peptide-pulsed DC vaccine is a safe and promising immunotherapy for ATL.",
keywords = "Adult T cell leukaemia/lymphoma, Cytotoxic T lymphocyte, Dendritic cell, Human T cell leukaemia virus type-I, Tumour vaccine",
author = "Youko Suehiro and Atsuhiko Hasegawa and Tadafumi Iino and Amane Sasada and Nobukazu Watanabe and Masao Matsuoka and Ayako Takamori and Ryuji Tanosaki and Atae Utsunomiya and Ilseung Choi and Tetsuya Fukuda and Osamu Miura and Shigeo Takaishi and Takanori Teshima and Koichi Akashi and Mari Kannagi and Naokuni Uike and Jun Okamura",
year = "2015",
month = "5",
day = "1",
doi = "10.1111/bjh.13302",
language = "English",
volume = "169",
pages = "356--367",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Clinical outcomes of a novel therapeutic vaccine with Tax peptide-pulsed dendritic cells for adult T cell leukaemia/lymphoma in a pilot study

AU - Suehiro, Youko

AU - Hasegawa, Atsuhiko

AU - Iino, Tadafumi

AU - Sasada, Amane

AU - Watanabe, Nobukazu

AU - Matsuoka, Masao

AU - Takamori, Ayako

AU - Tanosaki, Ryuji

AU - Utsunomiya, Atae

AU - Choi, Ilseung

AU - Fukuda, Tetsuya

AU - Miura, Osamu

AU - Takaishi, Shigeo

AU - Teshima, Takanori

AU - Akashi, Koichi

AU - Kannagi, Mari

AU - Uike, Naokuni

AU - Okamura, Jun

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Adult T cell leukaemia/lymphoma (ATL) is a human T cell leukaemia virus type-I (HTLV-I)-infected T cell malignancy with poor prognosis. We herein developed a novel therapeutic vaccine designed to augment an HTLV-I Tax-specific cytotoxic T lymphocyte (CTL) response that has been implicated in anti-ATL effects, and conducted a pilot study to investigate its safety and efficacy. Three previously treated ATL patients, classified as intermediate- to high-risk, were subcutaneously administered with the vaccine, consisting of autologous dendritic cells (DCs) pulsed with Tax peptides corresponding to the CTL epitopes. In all patients, the performance status improved after vaccination without severe adverse events, and Tax-specific CTL responses were observed with peaks at 16-20 weeks. Two patients achieved partial remission in the first 8 weeks, one of whom later achieved complete remission, maintaining their remission status without any additional chemotherapy 24 and 19 months after vaccination, respectively. The third patient, whose tumour cells lacked the ability to express Tax at biopsy, obtained stable disease in the first 8 weeks and later developed slowly progressive disease although additional therapy was not required for 14 months. The clinical outcomes of this pilot study indicate that the Tax peptide-pulsed DC vaccine is a safe and promising immunotherapy for ATL.

AB - Adult T cell leukaemia/lymphoma (ATL) is a human T cell leukaemia virus type-I (HTLV-I)-infected T cell malignancy with poor prognosis. We herein developed a novel therapeutic vaccine designed to augment an HTLV-I Tax-specific cytotoxic T lymphocyte (CTL) response that has been implicated in anti-ATL effects, and conducted a pilot study to investigate its safety and efficacy. Three previously treated ATL patients, classified as intermediate- to high-risk, were subcutaneously administered with the vaccine, consisting of autologous dendritic cells (DCs) pulsed with Tax peptides corresponding to the CTL epitopes. In all patients, the performance status improved after vaccination without severe adverse events, and Tax-specific CTL responses were observed with peaks at 16-20 weeks. Two patients achieved partial remission in the first 8 weeks, one of whom later achieved complete remission, maintaining their remission status without any additional chemotherapy 24 and 19 months after vaccination, respectively. The third patient, whose tumour cells lacked the ability to express Tax at biopsy, obtained stable disease in the first 8 weeks and later developed slowly progressive disease although additional therapy was not required for 14 months. The clinical outcomes of this pilot study indicate that the Tax peptide-pulsed DC vaccine is a safe and promising immunotherapy for ATL.

KW - Adult T cell leukaemia/lymphoma

KW - Cytotoxic T lymphocyte

KW - Dendritic cell

KW - Human T cell leukaemia virus type-I

KW - Tumour vaccine

UR - http://www.scopus.com/inward/record.url?scp=84927694937&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927694937&partnerID=8YFLogxK

U2 - 10.1111/bjh.13302

DO - 10.1111/bjh.13302

M3 - Article

C2 - 25612920

AN - SCOPUS:84927694937

VL - 169

SP - 356

EP - 367

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 3

ER -